Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.38 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.38 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.38 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.34 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.33 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | JAK1 | P23458 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31503632 | 0.89 | CHRNB2 (0.40) | SMN1; SMN2CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL28696863 | 0.84 | SMN1; SMN2 (0.41) | SMN1; SMN2CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL21380100 | 0.83 | CHRNB2 (0.48) | SMN1; SMN2CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL86929 | 0.80 | SMN1; SMN2 (0.50) | SMN1; SMN2CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL62434 | 0.80 | SMN1; SMN2 (0.50) | SMN1; SMN2CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL17260724 | 0.79 | KDM2B (0.33) | HSD11B1KDM2B | |
| Water SCHEMBL28833621 | 0.78 | — | — | |
| SCHEMBL22280725 | 0.77 | TP53 (0.43) | SMN1; SMN2CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL442252 | 0.77 | TP53 (0.43) | SMN1; SMN2CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL22688494 | 0.77 | ANPEP (0.38) | SMN1; SMN2KDM2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6723848-B2 | TETRAHYDROBENZOFURAN OR TETRAHYDROBENZOTHIOPHEN OR TETRAHDYROBENZOPYRROLE COMPOUNDS CAN BE AROMATIZED WITH A HYDROGENATION CATALYST IN PRESENCE OF A HYDROGEN ACCEPTOR, DEACYLATION OF AMINO GROUP BY ADDITION OF AN AMINE GROUP | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2004-04-20 | — | — | US | claimed |
| US-12486277-B2 | CDK inhibitors and their use as pharmaceuticals | Prelude Therapeutis Incorporated (US) | 2025-12-02 | — | — | US | disclosed |
| US-20230242543-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | PRELUDE THERAPEUTICS INCORPORATED | 2023-08-03 | — | — | US | disclosed |
| US-20230242543-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | PRELUDE THERAPEUTICS INCORPORATED | 2023-08-03 | — | — | US | disclosed |
| US-20230242543-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | PRELUDE THERAPEUTICS INCORPORATED | 2023-08-03 | — | — | US | disclosed |
| US-11673893-B2 | CDK inhibitors and their use as pharmaceuticals | PRELUDE THERAPEUTICS INCORPORATED (US) | 2023-06-13 | — | — | US | disclosed |
| US-11673893-B2 | CDK inhibitors and their use as pharmaceuticals | PRELUDE THERAPEUTICS INCORPORATED (US) | 2023-06-13 | — | — | US | disclosed |
| US-11673893-B2 | CDK inhibitors and their use as pharmaceuticals | PRELUDE THERAPEUTICS INCORPORATED (US) | 2023-06-13 | — | — | US | disclosed |
| US-20230144528-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | PRELUDE THERAPEUTICS, INCORPORATED | 2023-05-11 | — | — | US | disclosed |
| US-20230144528-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | PRELUDE THERAPEUTICS, INCORPORATED | 2023-05-11 | — | — | US | disclosed |
| US-20220324830-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | PRELUDE THERAPEUTICS, INCORPORATED | 2022-10-13 | — | — | US | disclosed |
| CN-114786673-A | CDK inhibitors and their use as medicaments | 普莱鲁德疗法有限公司 | 2022-07-22 | — | — | CN | disclosed |
| EP-4028005-A1 | CDK INHIBITORS AND THEIR USE AS PHARMACEUTICALS | Prelude Therapeutics, Incorporated (US) | 2022-07-20 | — | — | EP | disclosed |
| CN-114478528-A | Aroyl-substituted tricyclic compound, preparation method and application thereof | 劲方医药科技(上海)有限公司 | 2022-05-13 | — | — | CN | disclosed |
| WO-2021050824-A1 | CDK INHIBITORS AND THEIR USE AS PHARMACEUTICALS | PRELUDE THERAPEUTICS INCORPORATED (US) | 2021-03-18 | — | — | WO | disclosed |
| WO-2021050824-A1 | CDK INHIBITORS AND THEIR USE AS PHARMACEUTICALS | PRELUDE THERAPEUTICS INCORPORATED (US) | 2021-03-18 | — | — | WO | disclosed |
| US-20210070761-A1 | CDK INHIBITORS AND THEIR USE AS PHARMACEUTICALS | PRELUDE THERAPEUTICS INCORPORATED | 2021-03-11 | — | — | US | disclosed |
| US-20210070761-A1 | CDK INHIBITORS AND THEIR USE AS PHARMACEUTICALS | PRELUDE THERAPEUTICS INCORPORATED | 2021-03-11 | — | — | US | disclosed |
| US-6723848-B2 | TETRAHYDROBENZOFURAN OR TETRAHYDROBENZOTHIOPHEN OR TETRAHDYROBENZOPYRROLE COMPOUNDS CAN BE AROMATIZED WITH A HYDROGENATION CATALYST IN PRESENCE OF A HYDROGEN ACCEPTOR, DEACYLATION OF AMINO GROUP BY ADDITION OF AN AMINE GROUP | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2004-04-20 | — | — | US | disclosed |
| US-20030078422-A1 | Method for producing benzo annelated heterocycles | MERCK PATENT GMBH (DE) | 2003-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11673893-B2 | CDK inhibitors and their use as pharmaceuticals | CDK6, CDK3, CDK9 | SMN1; SMN2 1821/4885CHRNB2 4487/4885CHRNA4 4475/4885 |
| US-20230144528-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | CDK6, CDK3, CDK9 | SMN1; SMN2 1821/4885CHRNB2 4487/4885CHRNA4 4475/4885 |
| US-20220324830-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | CDK6, CDK3, CDK9 | SMN1; SMN2 1821/4885CHRNB2 4487/4885CHRNA4 4475/4885 |
| US-12486277-B2 | CDK inhibitors and their use as pharmaceuticals | CDK6, CDK3, CDK9 | SMN1; SMN2 1821/4885CHRNB2 4487/4885CHRNA4 4475/4885 |
| US-20030078422-A1 | Method for producing benzo annelated heterocycles | NAT1, AFF1, SAT1 | SMN1; SMN2 3091/4885CHRNB2 1925/4885CHRNA4 1227/4885 |
| US-20230242543-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | CDK6, CDK3, CDK9 | SMN1; SMN2 1821/4885CHRNB2 4487/4885CHRNA4 4475/4885 |
| US-20210070761-A1 | CDK INHIBITORS AND THEIR USE AS PHARMACEUTICALS | CDK6, CDK3, CDK9 | SMN1; SMN2 1821/4885CHRNB2 4487/4885CHRNA4 4475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.